Description
Irinotecan is an analog of camptothecin that is used clinically to treat colon and ovarian cancers, among others. Irinotecan exhibits anticancer chemotherapeutic, anti-angiogenic, and immunosuppressive activities. Irinotecan inhibits DNA topoisomerase I and sensitizes tumors to the effects of radiation. In glioma models, irinotecan decreases the number of tumor vessels and decreases expression of VEGF and HIF-1α, inhibiting tumor growth. Irinotecan also moderates inhibition of dendritic cell differentiation and may produce cholinergic side effects, suggesting potential inhibition of acetylcholinesterase (AChE) as well.
References
Hu J, Kinn J, Zirakzadeh AA, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. 2013 Jun;172(3):490-9. PMID: 23600838.
Pan P, Li Y, Yu H, et al. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches. J Chem Inf Model. 2013 Apr 22;53(4):997-1006. PMID: 23521602.
Chen AY, Chen PM, Chen YJ. DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis. 2012 Aug;4(4):390-7. PMID: 22934142.
Chintala S, Tóth K, Cao S, et al. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. PMID: 20066420.
Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol. 1999 Dec;56(6):1346-53. PMID: 10570064.
